HIGHLIGHTS
- who: from the (UNIVERSITY) have published the research work: Metformin and breast cancer: an opportunity for pharmacogenetics, in the Journal: (JOURNAL)
SUMMARY
The findings of the MA.32 trial do not support adding metformin to standard adjuvant therapy in non-diabetic BC patients with early-stage disease. The results offered by the MA.32 study do not preclude the use of metformin to treat T2D in BC patients, which might alleviate some of the multi-faceted effects of diabetes in A potential beneficial effect of the anti-diabetic biguanide metformin across several cancer . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.